90 completed, 33 terminated, 10 active not recruiting, 10 recruiting. 86 Phase 1, 77 Phase 2, 13 Not applicable, 3 Phase 3, 1 Early Phase 1.
Follow Refractory Chronic Lymphocytic Leukemia: new trials by email Literature Review of Refractory Chronic Lymphocytic Leukemia trials Research Report on Refractory Chronic Lymphocytic Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Roginolisib Plus Obinutuzumab + Venetoclax in R/R CLL Roginolisib, Obinutuzumab, Venetoclax - Chronic Lymphocytic Leukemia (CLL), Refractory Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Not yet recruiting | Dana-Farber Cancer Institute | 40 | 2027-01-13 | 2026-09-29 |
| Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography - Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 20 | 2026-05-27 | 2026-10-06 |
| Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia Autologous Anti-CD19/CD20/CD22 CAR T-cells, Biospecimen Collection, Bone Marrow Aspiration - Blast Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive, Recurrent Acute Lymphoblastic Leukemia | Phase 1 | Active not recruiting | Ohio State University Comprehensive Cancer Center | 24 | 2026-01-14 | 2026-08-26 |
| Q702 for the Treatment of Patients With Hematologic Malignancies Axl/Mer/CSF1R Inhibitor Q702, Biospecimen Collection, Bone Marrow Aspiration - Hematopoietic and Lymphatic System Neoplasm, Histiocytic Sarcoma | Phase 1 | Recruiting | Mayo Clinic | 46 | 2025-08-27 | 2025-10-10 |
| Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography - Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma | Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 30 | 2025-06-02 | 2026-04-22 |
| Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies Biopsy, Biospecimen Collection, Bone Marrow Aspiration - Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma | Phase 1 | Terminated | Roswell Park Cancer Institute | 1 | 2024-11-26 | 2025-08-03 |
| B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies Autologous BAFFR-targeting CAR T Cells, Bendamustine, Biopsy - B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia | Phase 1 | Recruiting | Mayo Clinic | 27 | 2024-03-18 | 2026-02-13 |
| A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies BGB-21447 - Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma | Phase 1 | Terminated | BeOne Medicines | 51 | 2023-06-20 | 2026-07-14 |
| Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, The AVENUE-2 Trial Acalabrutinib, Venetoclax, Biospecimen Collection - Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma | Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 20 | 2023-05-31 | 2026-10-23 |
| CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies Autologous Anti-CD19 CAR-expressing T-lymphocytes IC19/1563, Bendamustine, Biospecimen Collection - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia | Phase 1 | Recruiting | Mayo Clinic | 25 | 2022-10-03 | 2026-06-09 |
| Ipilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia and Richter Transformation Ibrutinib, Ipilimumab, Nivolumab - Hematopoietic and Lymphoid Cell Neoplasm, Recurrent Chronic Lymphocytic Leukemia | Phase 1 | Withdrawn | M.D. Anderson Cancer Center | 2022-07-14 | 2025-02-28 | |
| Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies Anti-CD19/CD20/CD22 CAR T-Cells, Cyclophosphamide, Fludarabine Phosphate - Recurrent Acute Lymphoblastic Leukemia, Recurrent B Acute Lymphoblastic Leukemia | Phase 1 | Recruiting | Sumithira Vasu | 54 | 2022-06-30 | 2026-05-29 |
| Venetoclax Resistance Landscape in Chronic Lymphocytic Leukemia Chronic Lymphocytic Leukemia, CLL | Recruiting | University Hospital, Clermont-Ferrand | 50 | 2022-03-07 | 2024-01-09 | |
| A Study to Evaluate VIP152 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia or Richter Syndrome VIP152, BTKi - Relapsed Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia | Phase 1 | Terminated | Vincerx Pharma, Inc. | 6 | 2021-12-16 | 2023-11-18 |
| Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Cyclosporine - Acute Leukemia, Acute Lymphoblastic Leukemia | Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 60 | 2021-01-25 | 2026-05-29 |
| Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLL Acalabrutinib, Umbralisib, Ublituximab - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 2 | Active not recruiting | Jennifer R. Brown, MD, PhD | 29 | 2020-12-15 | 2026-02-25 |
| Daratumumab and Ibrutinib for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia, DIRECT Study Daratumumab, Ibrutinib - Recurrent Chronic Lymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Phase 2 | Terminated | Mayo Clinic | 8 | 2020-11-11 | 2025-12-30 |
| CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma Lenalidomide, Obinutuzumab, Oral Azacitidine - Indolent B-Cell Non-Hodgkin Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma | Phase 1 | Completed | Joseph Tuscano | 8 | 2020-10-23 | 2025-04-24 |
| Rituximab, Idelalisib, and Venetoclax in Relapsed/Refractory CLL/SLL Dose combination 1-1, dose combination 1-2, Dose combination 1-3 - Chronic Lymphocytic Leukemia, CLL | Phase 1 | Withdrawn | Virginia Commonwealth University | 2020-10-02 | 2021-11-09 | |
| Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Acalabrutinib, Obinutuzumab, Venetoclax - Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 168 | 2020-07-29 | 2026-09-10 |
Showing 20 of 159. Sign in to see all of them.
Leukemia, Lymphocytic, Chronic, B-Cell (159) · Lymphoma, Mantle-Cell (81) · Lymphoma, Follicular (77) · Lymphoma, Large B-Cell, Diffuse (75) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (72) · Lymphoma, B-Cell, Marginal Zone (65) · Lymphoma, Non-Hodgkin (65) · Burkitt Lymphoma (55) · Hodgkin Disease (52) · Waldenstrom Macroglobulinemia (52) · Leukemia, Myeloid, Acute (46) · Lymphoma, Large-Cell, Immunoblastic (45) · Multiple Myeloma (45) · Lymphoma, T-Cell, Cutaneous (44) · Mycosis Fungoides (42)
Chronic Disease (159) · Disease Attributes (159) · Hematologic Diseases (159) · Hemic and Lymphatic Diseases (159) · Immune System Diseases (159) · Immunoproliferative Disorders (159) · Neoplasms by Histologic Type (159) · Pathologic Processes (159) · Pathological Conditions, Signs and Symptoms (159) · Leukemia, B-Cell (158) · Leukemia, Lymphoid (158) · Lymphatic Diseases (158) · Lymphoproliferative Disorders (158) · Leukemia (156) · Neoplasms (155)
fludarabine phosphate (36) · Mycophenolic Acid (28) · Whole-Body Irradiation (28) · Cyclophosphamide (27) · Cyclosporine (20) · Peripheral Blood Stem Cell Transplantation (20) · Rituximab (20) · ibrutinib (14) · Tacrolimus (11) · Biopsy (10) · Cyclosporins (10) · Specimen Handling (10) · Lenalidomide (9) · Magnetic Resonance Spectroscopy (8) · fludarabine (8)
National Cancer Institute (NCI) (48) · Fred Hutchinson Cancer Center (35) · M.D. Anderson Cancer Center (9) · Mayo Clinic (8) · City of Hope Medical Center (6) · Roswell Park Cancer Institute (6) · Case Comprehensive Cancer Center (5) · Chinese PLA General Hospital (4) · Ohio State University Comprehensive Cancer Center (3) · Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium (2) · OHSU Knight Cancer Institute (2) · Wake Forest University Health Sciences (2) · Alexey Danilov, MD (1) · Amir Mortazavi (1) · BeOne Medicines (1)
United States (146) · Italy (11) · Germany (9) · China (7) · Denmark (4) · Canada (3) · Australia (1) · France (1) · New Zealand (1) · Poland (1)
Brenda Sandmaier (10) · David Maloney (8) · John Byrd (6) · Jennifer Woyach, MD (3) · Kristie Blum (3) · Mohamed Sorror (3) · Paul Martin (3) · Brenda Cooper (2) · Francis Giles (2) · George Chen (2) · Kerry Rogers, MD (2) · Maryam Fouladi (2) · Mazyar Shadman (2) · Neil Kay (2) · Nitin Jain (2)
PMID 32499241, PMID 34515338, PMID 19826119, PMID 22289993, PMID 24990615, PMID 39863139, PMID 17679729, PMID 18974373, PMID 19679883, PMID 19900571, PMID 20837940, PMID 21072184, PMID 22259028, PMID 22308288, PMID 23256542, PMID 23393050, PMID 23887852, PMID 24474568, PMID 25085357, PMID 25317870, PMID 25444722, PMID 25596730, PMID 26451310, PMID 26853648, PMID 26943915, PMID 27111235, PMID 28270022, PMID 28314788, PMID 28424162, PMID 28817727, PMID 29038338, PMID 29263894, PMID 29572391, PMID 29599530, PMID 30111609, PMID 30562587, PMID 30728140, PMID 30729531, PMID 30782611, PMID 31076448, PMID 31141631, PMID 31248843, PMID 31481800, PMID 31617432, PMID 31648294, PMID 31815579, PMID 32245502, PMID 32603426, PMID 32628342, PMID 32795224
P30CA015704 (22), U01CA076576 (11), P01CA018029 (9), P30CA016058 (7), P01CA078902 (5), U10CA025224 (4), N01CM62207 (3), P30CA015083 (3), P30CA016672 (3), U01CA062502 (3), U01CA062505 (3), U01CA097452 (3), N01CM62201 (2), N01CM62202 (2), P30CA033572 (2)